Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $9 to $7.
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $9 to $7.